| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 4.8 | 0.4 |
| Net income | -51.2 | -50.5 |
| EPS (diluted, $ a share) | $-0.53 | $-0.62 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +1074.1% |
|---|
10-Q filed with the SEC, NASDAQ: MGTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
MeiraGTx Holdings plc: key numbers
- Share price
- $8.46Close, Nov 17
- Market cap
- $827M
- Shares outstanding
- 97.73MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from MeiraGTx Holdings plc
All →MeiraGTx Holdings Financial Results
MeiraGTx reported third quarter 2026 financial results and provided a regulatory update for its lead candidate bota-vec, with an MAA submission to the EMA expected in December 2026 and a BLA submission to the FDA in Q1 2027. The company is preparing for a potential commercial launch of bota-vec for XLRP in late 2027 while advancing its Phase 2 AQUAx2 study for radiation-induced xerostomia.
“We are pleased to report that we have now completed much of the work towards submission of full global regulatory filings with the EMA and FDA for bota-vec for the treatment of XLRP. The MAA dossier is complete and awaiting submission and the BLA is expected to follow early next year.”
Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx
“We are actively preparing for our pivotal Phase 2 AQUAx2 12-month data readout for the treatment of radiation-induced xerostomia in mid-2027. As we progress these two lead programs through filing for potential approval and commercialization, we are also advancing several programs towards IND.”
Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx
MeiraGTx Holdings CFO & COO Richard Giroux Sells $557K of Stock
Richard Giroux, CFO & COO, sold 56,000 shares of MeiraGTx Holdings plc at $9.95 a share, worth $557K in total on Oct 20, 2026. Shares held after the trade: 852,530 (-6.2%).
- Value
- $557K
- Shares
- 56,000
- Price
- $9.95
- Role
- CFO & COO
- Holding change
- -6.2%
- Trade date
- Oct 20, 2026
MeiraGTx Holdings Chief Sci Ofcr, Ophthalmology Stuart Naylor Sells $294K of Stock
Stuart Naylor, Chief Sci Ofcr, Ophthalmology, sold 27,659 shares of MeiraGTx Holdings plc at $10.64 a share, worth $294K in total on Oct 6, 2026. Shares held after the trade: 613,187 (-4.3%).
- Value
- $294K
- Shares
- 27,659
- Price
- $10.64
- Role
- Chief Sci Ofcr, Ophthalmology
- Holding change
- -4.3%
- Trade date
- Oct 6, 2026
MeiraGTx Holdings Leadership Change
MeiraGTx Holdings plc appointed Alan M. Sebulsky to its Board of Directors as a Class I director, effective September 23, 2026. Mr. Sebulsky, a veteran healthcare portfolio manager with over 40 years of experience, will also serve on the company's Science and Technology Committee.
- Counterparty
- Alan M. Sebulsky